Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: a case-series of 16 patients
- PMID: 22772615
- DOI: 10.4103/0378-6323.98075
Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: a case-series of 16 patients
Abstract
Background: Organ transplant recipients (OTR) are at high risk of developing cutaneous neoplasms. Topical photodynamic therapy (PDT) has been used for the treatment of actinic keratosis (AK) in OTR.
Aims: The objective was to evaluate the efficacy of PDT with methylaminolevulinate (MAL) in the treatment of facial AK in OTR. As a secondary objective, we wanted to evaluate the usefulness of topical PDT in the reduction of photodamage in OTR.
Methods: A prospective, single center, single arm study was made. 16 OTR were included. Topical PDT was applied for 1 or 2 cycles depending on the patient's characteristics. An evaluation of AK was made at visits pre-treatment, at 12 weeks and at 24 weeks. Photodamage was measured with multispectral image technique (SkinCare).
Results: A complete response rate of 100% was achieved for AK in all patients; it persisted without change at 12 and 24 weeks of follow-up. 62.5% of patients improved their photodamage as measured by SkinCare®, but this result was not statistically significant (P = 0.12). All patients had high level of satisfaction at the end of the therapy.
Conclusions: MAL-PDT is an effective therapy for the treatment of AK in OTRs. It can reduce photodamage in this group of patients, but these results were not statistically significant.
Similar articles
-
The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp.J Dermatolog Treat. 2010 Jul;21(4):252-7. doi: 10.3109/09546630903271555. J Dermatolog Treat. 2010. PMID: 19832288
-
Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial.Br J Dermatol. 2014 Nov;171(5):1164-71. doi: 10.1111/bjd.13138. Epub 2014 Oct 20. Br J Dermatol. 2014. PMID: 24861492 Clinical Trial.
-
Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy.J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1926-32. doi: 10.1111/jdv.13076. Epub 2015 Mar 23. J Eur Acad Dermatol Venereol. 2015. PMID: 25809617
-
Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia.Australas J Dermatol. 2016 Aug;57(3):167-74. doi: 10.1111/ajd.12354. Epub 2015 May 31. Australas J Dermatol. 2016. PMID: 26033230 Free PMC article. Review.
-
Methyl aminolevulinate: actinic keratoses and Bowen's disease.Dermatol Clin. 2007 Jan;25(1):81-7. doi: 10.1016/j.det.2006.09.009. Dermatol Clin. 2007. PMID: 17126745 Review.
Cited by
-
Exploring Anti-Aging Effects of Topical Treatments for Actinic Keratosis.Medicina (Kaunas). 2025 Jan 24;61(2):207. doi: 10.3390/medicina61020207. Medicina (Kaunas). 2025. PMID: 40005324 Free PMC article. Review.
-
Topical Immunotherapy for Actinic Keratosis and Field Cancerization.Cancers (Basel). 2024 Mar 12;16(6):1133. doi: 10.3390/cancers16061133. Cancers (Basel). 2024. PMID: 38539468 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials